Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy

Menopause

Volumn 11, Issue 5, 2004, Pages 531-535

  Dimitrakakis, Constantine ^a   Jones, Robert A ^b   Liu, Aiyi ^a   Bondy, Carolyn A ^a,c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b Memorial Medical Center   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Androgen; Estrogen; Hormone therapy; Menopause

Indexed keywords

ESTROGEN; GESTAGEN; TESTOSTERONE;

ADULT; ARTICLE; AUSTRALIA; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; FEMALE; HIRSUTISM; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL LITERATURE; OVARY INSUFFICIENCY; POSTMENOPAUSE; AGE DISTRIBUTION; AGED; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; ESTROGEN THERAPY; INCIDENCE; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AUSTRALIA; BREAST NEOPLASMS; COHORT STUDIES; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; POSTMENOPAUSE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TESTOSTERONE;

EID: 14944359093     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000119983.48235.D3     Document Type: Article

References (13)

1. Dimitrakakis C, Zhou J, Bondy CA. Androgens and mammary growth and neoplasia. Fertil Steril 2002;77(Suppl 4):26-33.
2. Jayo MJ, Register TC, Hughes CL, et al. Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Investig 2000;7:257-265.
3. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000; 14:1725-1730.
4. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-298.
5. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Braunstein GD. Androgen insufficiency in women: summary of critical issues. Fertil Steril 2002;77:94-99.
8. Davis SR, Burger HG, McCloud P, Strauss BJ, Burger H. The rationale for physiological testosterone replacement in women Baillieres Clin Endocrinol Metab 1998;12:391-405.
9. Fleiss JL, Kingman A. Statistical management of data in clinical research. Crit Rev Oral Biol Med 1990;1:55-66.
10. Australia's Breast Cancer Statistics, 2002. National Breast Cancer Center. Available at: http://www.nbcc.org.au. Accessed July 25, 2003.
11. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
12. Gail MH. The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann N Y Acad Sci 2001;949:286-291.
13. Labrie F, Simard J, de Launoit Y, et al. Androgens and breast cancer. Cancer Detect Prev 1992;16:31-38.